A Democratic bill with 1 Republican cosponsor · See the cosponsor
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The "Right Drug Dose Now Act of 2025" aims to update the National Action Plan for Adverse Drug Event Prevention. It focuses on incorporating advancements in pharmacogenomic research and testing into medical practices. The bill directs the Secretary of Health and Human Services to update national action plans and provide guidance to health care professionals. Additionally, it seeks to improve electronic health record systems to better utilize pharmacogenomic information. The legislation also includes mandates to update the FDA Adverse Event Reporting System to be more patient-friendly. Finally, it calls for studies on including drug-gene interaction information on drug labels.
Yes· 3 of 6
- Scored +6
Does this make health care easier to get in general?
The bill improves healthcare quality and safety by integrating pharmacogenomic insights into clinical practice and electronic health records.
- Scored +5
Does this give people more protection from unfair business practices?
The bill enhances consumer protection by providing tools to prevent adverse drug reactions through pharmacogenomics.
- Scored +3
Does this put more money into medical research?
The bill promotes the application of scientific research in pharmacogenomics to clinical settings.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Improved Prevention of Adverse Drug Reactions: The bill seeks to use pharmacogenomic testing and clinical decision support as evidence-based prevention tools to help avoid harmful drug reactions (Section 3).
-
Better Informed Health Care Professionals: The Secretary will issue guidance to various medical professionals on topics like when to refer patients to genetics providers and how to incorporate pharmacogenomics into medication management (Section 4).
-
Enhanced Electronic Health Record Alerts: The bill directs the creation of guidance for electronic prescribing systems to automatically indicate when pharmacogenomic testing is appropriate or identify drug-gene associations before a medication order is completed (Section 5a).
-
Easier Adverse Event Reporting for Patients: The bill directs the creation of patient-friendly electronic options, such as mobile device applications, to report adverse drug events (Section 5d).
-
Improved Drug Labeling Information: Through a GAO study, the bill looks toward how the FDA can include and update information regarding drug-gene interactions on drug labels (Section 5e).
Potential Negative Impacts for People
- No specific negative impacts or burdens are explicitly mentioned in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Healthcare
- Does this make health care easier to get in general? — The bill improves healthcare quality and safety by integrating pharmacogenomic insights into clinical practice and electronic health records. Does this put more money into medical research? — The bill promotes the application of scientific research in pharmacogenomics to clinical settings.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill enhances consumer protection by providing tools to prevent adverse drug reactions through pharmacogenomics.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill requires reports to Congress regarding the progress of adverse drug event prevention. Does this give the federal government more power? — The bill expands the role of the Secretary of HHS and the FDA in clinical guidance and drug labeling.
- Education And Technology
- Does this put more money into scientific research? — The bill directs studies and updates to include pharmacogenomic information, supporting medical science integration.
- 3/27/2025
- Referred to the House Committee on Energy and Commerce.
- 1 Cosponsor added.
- Introduced in House
Dan CrenshawRepublican · Texas